We are Vivodyne.

Dr. Georgescu spearheads Vivodyne’s vision of reshaping therapeutics development. The loss of translation between animal studies and human trials compelled him to co-found Vivodyne in 2020 and create an entirely new platform from the ground up. With a Ph.D. from Dr. Huh’s esteemed organ-chip research group at the University of Pennsylvania, his expertise lies in human-tissue engineering, robotics, and machine learning. His prior achievements include sending lab-grown tissues with NASA to space and developing DNA synthesis chips that remain industry staples to this day.

Dr. Dan Huh is an internationally acclaimed bioengineer and designer widely known as a pioneer of organ-on-a-chip technology. While at Harvard he published a paper in Science presenting the first “lung-on-a-chip” model as a proof of concept that ultimately kickstarted the whole field of organs-on-chips. He is a renowned Professor in the Department of Bioengineering at the University of Pennsylvania. At Vivodyne, his research group focuses on developing new and innovative microengineered models of human physiological systems. His work has been recognized by many awards, including the Bernard Langer Distinguished Lectureship, Lush Prize, and the McPherson Distinguished Lectureship, just to name a few.

Julie has a track record of building and scaling high performance teams for both startups and enterprises across finance, tech, and biotech sectors. Her focus is on implementing strategic mechanisms and processes that enable consistent execution and sustainable growth. At Vivodyne, she’s responsible for all operational functions including strategic planning, finance, people, facilities, and business operations. Before Vivodyne, she led operations at Resilience during its hyper-growth scale-up period to over 3,000 workers. At AWS, she founded the global operations team to support enterprise customers and went on to lead the global strategy and operations for the Startup and VC side of the business. Julie is Vice Chair of the Board at the Ali Forney Center and an Executive Committee member for the University of New Hampshire Athletics Board.

Dr. Bahinski’s career spans academic research and large pharma, with more than 25 years of experience in the pharmaceutical industry. He served on the Advanced Technology Team at Harvard’s Wyss Institute, leading DARPA, and FDA collaborative efforts in development of organ chip systems. He has also served on several advisory boards and is currently member of the Science Board of the US FDA and formerly of the US EPA Board of Scientific Counselors. He is a member of the Editorial Board of the journal Applied In Vitro Toxicology. Dr. Bahinski is author/co-author of over 45 publications including peer-reviewed articles and book chapters.

Sanja is a successful product leader with extensive experience building, launching and managing digital products across biotech, healthtech and proptech sectors. Within Vivodyne, she assumes the pivotal role of setting the strategic blueprint for its software, data, AI and infrastructure products. Previously, she led her own Product Consultancy to help dozens of technology companies identify product-market gaps, re-define their roadmaps and work closely with engineering, UI/UX and marketing to bring them to market. Prior to this, she was the founding VP of Product at Dealtap, overseeing the development of their SaaS platform from its inception, which led to a fourfold increase in revenue and $13.5M in Series A financing.

Andrew brings over two decades of expertise pioneering R&D in the semiconductor, biotechnology and MEMS industries. At Vivodyne, Andrew spearheads the development and implementation of cutting-edge robotic technology crucial for advancing human organ tissue production for drug discovery. Previously, he played pivotal roles in groundbreaking startups, including the design and launch of Berkeley Lights' innovative Beacon platform, revolutionizing biologics development and ultimately leading to an IPO. With his unique expertise in motion, vision, and microfluidics, Andrew is primed to drive Vivodyne's mission at the convergence of tissue engineering, robotic automation, and AI, fostering a new era of biotechnological innovation.

Sean is a scientist, engineer, and applied mathematician who leads our efforts to discover and de-risk therapeutics at scale through AI and related technologies. He and his team automate the analysis and understanding of human biology, physiology, and pathophysiology and the prediction of human outcomes in response to pharmacologic perturbations. Sean joins us from Flagship Pioneering where he architected AI, cloud, and scientific computing capabilities across their early-stage portfolio. Earlier he was at Amazon Web Services where provided technical guidance to hundreds of healthcare and life science customers. Pre-AWS, Sean played a pivotal role in building the tools that enabled biological imaging and genomics breakthroughs at HHMI/Janelia Labs, JCVI and Celera. He holds a PhD in Neuroscience from Yale and dual bachelor's degrees from MIT in Biology and EECS.

Andrew is a seasoned finance leader with a track record of driving high-growth technology startups towards financial success. He has raised over $300 million in equity and debt financing, built and scaled finance teams, and implemented financial strategies that contributed to company growth and exits. At Vivodyne, he oversees financial planning, analysis, accounting, and cash management. Previously, he honed his expertise maturing finance functions at Groq, Sense Photonics, and Ceterus, following a career as a capital markets investment banker in the industrial and technology sectors.